At a glance
- Originator Bristol-Myers Squibb
- Class Anti-inflammatories
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atopic dermatitis; Inflammation; Psoriasis
Most Recent Events
- 23 May 2000 No-Development-Reported for Atopic dermatitis in USA (Unknown route)
- 23 May 2000 No-Development-Reported for Inflammation in USA (Unknown route)
- 23 May 2000 No-Development-Reported for Psoriasis in USA (Unknown route)